[Pharmacological control of biosynthesis pathway of mevalonate: effect on the proliferation of arterial smooth muscle cells]. 1997

A Corsini, and L Arnaboldi, and P Quarato, and N Ferri, and A Granata, and R Fumagalli, and R Paoletti
Institut des Sciences Pharmacologiques, Université de Milan, Italie. corsinia@isfunix.farma.unimi.it

The role of mevalonic acid (MVA) and its products (isoprenoids) in cell proliferation prompted us to investigate the effect of drugs affecting diverse enzymatic steps of the MVA pathway on rat aorta smooth muscle cell (SMC) proliferation. Competitive inhibitors of HMG-CoA reductase (statins) decreased SMC proliferation in a dose-dependent manner. The inhibitory effect induced by simvastatin 3.5 microM (70% +/- 3.8 decrease) was prevented by addition of 100 microM MVA, (100% +/- 2.3), 10 microM farnesol (F-OH) (85% +/- 1.2) and 5 microM of all-trans geranylgeraniol (GG-OH) (precursor of prenylated proteins) (81% +/- 1.1), but not by 2-cis GG-OH (precursor of dolichols), squalene and ubiquinone. The same inhibitory effect was obtained with 6-fluoromevalonate (1-50 microM), an inhibitor of MVA-PP decarboxylase. Squalestatin 1 (1-25 microM) and NB-598 (1-10 microM), potent squalene synthase and epoxidase inhibitors, respectively, caused a complete inhibition of cholesterol synthesis without affecting SMC proliferation. Finally, BZA-5B (10-50 microM) a specific inhibitor of protein farnesyl tranferase (PFTase), inhibited SMC proliferation in a dose- (10-50 microM) and time-dependent manner, reaching 52% +/- 6.3 inhibition after 9 days, in the presence of 50 microM BZA-5B, without affecting cholesterol synthesis. This effect was partially prevented by mevalonate (76% +/- 3.2) and GG-OH (87% +/- 7.3) but not by F-OH. On the other hand, SMC proliferation was not affected by the closely related compound BZA-7B (93% +/- 4), which does not inhibit PFTase. Taken together, these findings support the involvement of specific isoprenoid metabolites, probably through farnesylated and geranylgeranylated proteins in cell proliferation.

UI MeSH Term Description Entries
D008297 Male Males
D008798 Mevalonic Acid A dihydroxy monocarboxylic acid and precursor in the biosynthetic pathway known as the mevalonate pathway, which produces terpenes and steroids that are vital for diverse cellular functions. Mevalonate,Acid, Mevalonic
D009131 Muscle, Smooth, Vascular The nonstriated involuntary muscle tissue of blood vessels. Vascular Smooth Muscle,Muscle, Vascular Smooth,Muscles, Vascular Smooth,Smooth Muscle, Vascular,Smooth Muscles, Vascular,Vascular Smooth Muscles
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001011 Aorta The main trunk of the systemic arteries. Aortas

Related Publications

A Corsini, and L Arnaboldi, and P Quarato, and N Ferri, and A Granata, and R Fumagalli, and R Paoletti
February 1975, Circulation research,
A Corsini, and L Arnaboldi, and P Quarato, and N Ferri, and A Granata, and R Fumagalli, and R Paoletti
January 1977, Progress in biochemical pharmacology,
A Corsini, and L Arnaboldi, and P Quarato, and N Ferri, and A Granata, and R Fumagalli, and R Paoletti
January 1995, Journal of cardiovascular pharmacology,
A Corsini, and L Arnaboldi, and P Quarato, and N Ferri, and A Granata, and R Fumagalli, and R Paoletti
August 2019, Immunopharmacology and immunotoxicology,
A Corsini, and L Arnaboldi, and P Quarato, and N Ferri, and A Granata, and R Fumagalli, and R Paoletti
May 1991, Annales de cardiologie et d'angeiologie,
A Corsini, and L Arnaboldi, and P Quarato, and N Ferri, and A Granata, and R Fumagalli, and R Paoletti
July 1998, Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine,
A Corsini, and L Arnaboldi, and P Quarato, and N Ferri, and A Granata, and R Fumagalli, and R Paoletti
August 2006, Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue,
A Corsini, and L Arnaboldi, and P Quarato, and N Ferri, and A Granata, and R Fumagalli, and R Paoletti
February 2001, Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology,
A Corsini, and L Arnaboldi, and P Quarato, and N Ferri, and A Granata, and R Fumagalli, and R Paoletti
October 2023, Current medical science,
A Corsini, and L Arnaboldi, and P Quarato, and N Ferri, and A Granata, and R Fumagalli, and R Paoletti
October 1999, Zhongguo yao li xue bao = Acta pharmacologica Sinica,
Copied contents to your clipboard!